https://www.selleckchem.com/pr....oducts/MGCD0103(Moce
The combination of curcumin and apigenin is an effective potential therapeutic for cervical cancers. Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation have been shown to have a good response to erlotinib, a receptor tyrosine kinase inhibitor of EGFR. In this study, we found that the cell death pathways activated by erlotinib in 2D and 3D culture systems are different. The cell death pathways induced by erlotinib were evaluated by flow cytometry and immunoblotting in both 2D and 3D c
Like
Comment
Share
